253 related articles for article (PubMed ID: 38305808)
1. Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures.
Dong Y; Wu X; Xu C; Hameed Y; Abdel-Maksoud MA; Almanaa TN; Kotob MH; Al-Qahtani WH; Mahmoud AM; Cho WC; Li C
Aging (Albany NY); 2024 Feb; 16(3):2591-2616. PubMed ID: 38305808
[TBL] [Abstract][Full Text] [Related]
2. Clinical value of anoikis-related genes and molecular subtypes identification in bladder urothelial carcinoma and
Dong Y; Xu C; Su G; Li Y; Yan B; Liu Y; Yin T; Mou S; Mei H
Front Immunol; 2023; 14():1122570. PubMed ID: 37275895
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Benefits and Prognostic Value of a Model Based on 7 Immune-associated Genes in Bladder Cancer.
Cao M; Cao Y; Xue S; Zhang Q; Zhang H; Xue W
Altern Ther Health Med; 2024 Apr; 30(4):130-138. PubMed ID: 38518167
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
Chen L; Lin J; Wen Y; Chen Y; Chen CB
Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
[TBL] [Abstract][Full Text] [Related]
5. Construction and validation of a bladder cancer risk model based on autophagy-related genes.
Shen C; Yan Y; Yang S; Wang Z; Wu Z; Li Z; Zhang Z; Lin Y; Li P; Hu H
Funct Integr Genomics; 2023 Jan; 23(1):46. PubMed ID: 36689018
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive
Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B
Front Immunol; 2022; 13():931906. PubMed ID: 35958598
[TBL] [Abstract][Full Text] [Related]
7. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
Front Immunol; 2022; 13():916800. PubMed ID: 35860239
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
Li C; Wan Z; Deng Q; Li Z; Wang Y
Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of telomerase related lncRNAs signature to predict prognosis and tumor immunotherapy response in bladder cancer.
Chen X; Qin Z; Zhu X; Wang L; Li C; Wang H
Sci Rep; 2023 Dec; 13(1):21816. PubMed ID: 38071230
[TBL] [Abstract][Full Text] [Related]
10. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
11. In silico development and experimental validation of a novel 7-gene signature based on PI3K pathway-related genes in bladder cancer.
Wang L; Wang Y; Bi J
Funct Integr Genomics; 2022 Oct; 22(5):797-811. PubMed ID: 35896848
[TBL] [Abstract][Full Text] [Related]
12. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
Tan Z; Fu S; Zuo J; Wang J; Wang H
Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
[TBL] [Abstract][Full Text] [Related]
13. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
14. Identification of a Novel Tumor Microenvironment Prognostic Signature for Bladder Urothelial Carcinoma.
Xu C; Pei D; Liu Y; Yu Y; Guo J; Liu N; Kang Z
Front Oncol; 2022; 12():818860. PubMed ID: 35299749
[TBL] [Abstract][Full Text] [Related]
15. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
Front Oncol; 2023; 13():972558. PubMed ID: 37064115
[TBL] [Abstract][Full Text] [Related]
17. Clinical Eosinophil-Associated Genes can Serve as a Reliable Predictor of Bladder Urothelial Cancer.
Xu C; Song L; Peng H; Yang Y; Liu Y; Pei D; Guo J; Liu N; Liu J; Li X; Li C; Kang Z
Front Mol Biosci; 2022; 9():963455. PubMed ID: 35936781
[No Abstract] [Full Text] [Related]
18. TFRC, associated with hypoxia and immune, is a prognostic factor and potential therapeutic target for bladder cancer.
Tang R; Wang H; Liu J; Song L; Hou H; Liu M; Wang J; Wang J
Eur J Med Res; 2024 Feb; 29(1):112. PubMed ID: 38336764
[TBL] [Abstract][Full Text] [Related]
19. Identification of a glycolysis- and lactate-related gene signature for predicting prognosis, immune microenvironment, and drug candidates in colon adenocarcinoma.
Liu C; Liu D; Wang F; Xie J; Liu Y; Wang H; Rong J; Xie J; Wang J; Zeng R; Zhou F; Peng J; Xie Y
Front Cell Dev Biol; 2022; 10():971992. PubMed ID: 36081904
[No Abstract] [Full Text] [Related]
20. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
Pan G; Xie H; Xia Y
Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]